Related Experiment Video

Updated: Aug 26, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
09:53

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge

Jude E Uzonna1, Gerald F Späth, Stephen M Beverley

  • 1Department of Pathobiology, University of Pennsylvania, Philadelphia, PA 19104, USA.

Journal of Immunology (Baltimore, Md. : 1950)
|March 9, 2004
PubMed

Insights

Attenuated Leishmania parasites lacking key surface molecules can persist without causing disease. These modified parasites successfully protected mice from virulent Leishmania major infection, suggesting a new strategy for leishmaniasis vaccines.

Area of Science:

  • Immunology
  • Parasitology
  • Vaccine Development

Background:

  • Long-term immunity to Leishmania parasites is challenging to achieve.
  • Previous attempts to create safe, persistent attenuated Leishmania strains have faced limitations.

Purpose of the Study:

  • To evaluate the protective potential of Leishmania major mutants lacking lipophosphoglycan (lpg2-) against virulent L. major challenge.
  • To determine if these attenuated parasites can induce protective immunity in the absence of a strong Th1 response.

Main Methods:

  • Generation of Leishmania major mutants deficient in lipophosphoglycan and secreted phosphoglycans (lpg2-).
  • Infection of BALB/c mice with attenuated lpg2- parasites.
  • Assessment of immune cell responses (IL-4, IL-10, IFN-gamma) to leishmanial antigens.
  • Challenge of infected mice with virulent L. major to evaluate protection.

Main Results:

  • lpg2- mutants persisted indefinitely in mice without causing disease.
  • Immune cells from lpg2--infected mice produced minimal IL-4, IL-10, and IFN-gamma.
  • Mice infected with lpg2- parasites were protected against challenge with virulent L. major.

Conclusions:

  • Attenuated Leishmania parasites (lpg2-) can induce long-term protection against leishmaniasis.
  • This protective immunity can be maintained even without a robust Th1 immune response.
  • lpg2- mutants represent a promising candidate for developing novel leishmaniasis vaccines.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites10:01

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites

Published on: March 16, 2018

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...